Tadarise
In brief
- Tadarise is not licensed in the UK; tadalafil is a prescription-only medicine in the UK.
- Tadarise is used to treat erectile dysfunction (and Super Tadarise combines tadalafil with dapoxetine for premature ejaculation). Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor that increases cGMP levels in penile tissue, improving blood flow and facilitating erection; dapoxetine is a short‑acting SSRI that can delay ejaculation.
- The usual dose for erectile dysfunction is 10–20 mg taken as needed (start at 10 mg in elderly or those with hepatic/renal impairment); do not exceed one dose per 24 hours. Super Tadarise combi tablets contain tadalafil 20 mg + dapoxetine 60 mg and are taken as indicated for premature ejaculation.
- Administration is oral — tablets or effervescent tablets to be taken by mouth, usually with water.
- The effect usually begins within 30–60 minutes after dosing.
- The duration of action can last up to 36 hours.
- Avoid excessive alcohol around the time of dosing — alcohol can increase dizziness, lower blood pressure, worsen side effects and reduce sexual performance.
- The most common side effect is headache.
- Would you like to try Tadarise without a prescription?
Basic Tadarise information
- INN (international nonproprietary name): Tadalafil.
- Brand names available in the United Kingdom: Tadarise itself is not licensed in the UK; licensed tadalafil is available as generic tablets.
- ATC code: G04BE08.
- Forms and dosages: Tablets 5 mg, 10 mg, 20 mg; effervescent tablets; combination tablets Tadalafil 20 mg + Dapoxetine 60 mg (Super Tadarise).
- Manufacturers in the United Kingdom: Sunrise Remedies Pvt. Ltd. (manufacturer of Tadarise).
- Registration status in the United Kingdom: Not licensed in the UK.
- OTC / Rx classification: Tadalafil is a prescription-only medicine (POM) in the UK; legal sale in pharmacies requires a prescription.
Critical warnings and restrictions
High-risk groups (elderly, pregnancy, chronic illness)
Tadarise contains tadalafil, a prescription-only phosphodiesterase type‑5 (PDE5) inhibitor and must not be taken without clinical assessment.
Elderly patients over 65 years should start at a lower dose and be monitored closely because of increased sensitivity and comorbidity risks.
Tadalafil is not indicated in pregnancy or for women; safety in children is not established and paediatric use is not recommended.
Patients with significant hepatic or renal impairment require dose adjustment or specialist advice, and those with severe impairment should avoid tadalafil unless a specialist recommends otherwise.
People with hereditary retinal disorders such as retinitis pigmentosa, structural penile disorders like Peyronie’s disease, or unstable cardiovascular disease need careful review before starting tadalafil.
Interaction with activities (driving, workplace safety under UK law)
Tadalafil can cause dizziness and visual disturbances in some people, which can affect driving or operating machinery.
Patients must assess their own fitness to drive or work after taking tadalafil and must follow Driver and Vehicle Licensing Agency (DVLA) and MHRA advice if side effects occur.
If a patient experiences dizziness, fainting, or visual problems after taking tadalafil they should not drive and should seek medical advice.
Q&A — “Can I drive after taking it in the UK?”
Most people can drive after taking tadalafil if they feel well and have no dizziness or visual disturbance.
Avoid driving or operating machinery if you experience dizziness, syncope, or visual changes after taking the tablet.
Report significant side effects to your GP or pharmacist and use the MHRA Yellow Card scheme to report suspected adverse reactions.
- Absolute contraindications: concurrent nitrates, known hypersensitivity to tadalafil, unstable cardiovascular disease (recent myocardial infarction, stroke, unstable angina).
- Relative contraindications/use with caution: severe hepatic or renal impairment, retinitis pigmentosa, penile structural deformities, significant heart disease, uncontrolled blood pressure.
- Emergency red flags: priapism lasting >4 hours, chest pain or pressure, severe hypotension or syncope, sudden loss of vision or hearing.
Usage basics
INN, brand names available in the UK
The active ingredient is tadalafil (INN).
Tadarise is supplied as Tadarise 10, Tadarise 20, Super Tadarise and Tadarise Effervescent and is manufactured by Sunrise Remedies Pvt. Ltd.
Tadarise itself is not licensed in the UK.
Legal classification (POM, P, GSL)
Tadalafil is a prescription-only medicine (POM) in the UK.
Tadarise as a brand is not licensed by the MHRA.
- INN: International Nonproprietary Name — tadalafil.
- ATC: Anatomical Therapeutic Chemical code — G04BE08.
- POM: prescription-only medicine — tadalafil requires a prescription in the UK.
Dosing guide
Standard regimens (NHS guidelines)
Tadalafil for on‑demand use is usually 10–20 mg taken 30–60 minutes before sexual activity, with the effect lasting up to 36 hours.
Tadarise formulations are sold in 5 mg, 10 mg and 20 mg tablets and in effervescent forms according to supplier information.
Super Tadarise combines tadalafil 20 mg with dapoxetine 60 mg and is used where both erectile dysfunction and premature ejaculation are present.
Adjustments for comorbidities
Start elderly patients (>65 years) at 10 mg and titrate cautiously based on tolerability and efficacy.
In mild to moderate renal or hepatic impairment, a lower starting dose (10 mg) is recommended; avoid tadalafil in severe impairment or end-stage disease unless advised by a specialist.
Children under 18 years must not use tadalafil as safety and efficacy are not established.
| Patient category | Usual dosage (ED) | Notes on adjustments |
|---|---|---|
| Adults (18–65) | 10–20 mg as needed | Take 30–60 minutes before activity; do not exceed once daily. |
| Elderly (>65) | Start 10 mg | Cautious titration according to tolerance. |
| Hepatic impairment | Start 10 mg or less | Avoid if severe impairment. |
| Renal impairment | Mild/moderate: 10 mg | Avoid if severe or ESRD. |
| Children (<18) | Not indicated | Safety and efficacy not established. |
Q&A — “What if I miss a dose?”
For on‑demand dosing a “missed dose” instruction is not applicable; take a tablet before planned sexual activity.
If using a daily tadalafil regimen (rare and not standard for Tadarise) take the missed dose when remembered unless it is close to the next dose and do not double doses.
Seek urgent care for overdose signs such as a persistent erection, severe dizziness or sudden vision loss.
- Pre‑treatment checklist: cardiac history, current medications (especially nitrates), hepatic and renal function.
- Document informed consent and counsel on common adverse effects before first dispense.
Interaction chart
Food and drinks (alcohol, tea/coffee, diet habits)
Heavy alcohol use increases the risk of dizziness, syncope and reduced erectile response when combined with tadalafil.
Large grapefruit intake may affect CYP metabolism for some medicines and warrants moderation, though grapefruit specifically affects certain CYP3A4 substrates.
Caffeine and tea have minimal direct interaction with tadalafil but can add to overall stimulant effects and anxiety in some patients.
Common drug conflicts
Major conflicts include nitrates, which are an absolute contraindication because of severe hypotension risk.
Potent CYP3A4 inhibitors, such as some azole antifungals and ritonavir, can raise tadalafil plasma levels and require dose adjustment or avoidance.
Alpha‑blockers used for urinary symptoms can interact and increase the risk of symptomatic hypotension if combined with tadalafil.
| Drug | Interaction | Clinical action |
|---|---|---|
| Nitrates | Severe hypotension | Absolute contraindication; do not co‑prescribe. |
| Ritonavir, protease inhibitors | Increased tadalafil levels via CYP3A4 inhibition | Avoid or reduce dose; consult specialist. |
| Azole antifungals (e.g. ketoconazole) | Raised tadalafil exposure | Consider lower dose or alternative treatment. |
| Alpha‑blockers | Risk of symptomatic hypotension | Start with low dose of either drug; monitor blood pressure. |
- Checklist for consultation: nitrates, alpha‑blockers, HIV protease inhibitors, potent CYP3A4 inhibitors or inducers.
- Pharmacists should review all current medicines before supply.
Legal status and availability in the UK
In our online pharmacy, Tadarise is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Mechanism and pharmacology
Simplified explanation
Tadalafil is a phosphodiesterase type‑5 (PDE5) inhibitor that enhances the normal erectile response to sexual stimulation by increasing cyclic guanosine monophosphate (cGMP) levels in penile tissue.
This increase in cGMP leads to relaxation of smooth muscle in the corpus cavernosum and improved blood flow, supporting erection on sexual stimulation.
Onset is typically 30–60 minutes with effects lasting up to 36 hours, allowing a broader window for sexual activity than shorter‑acting PDE5 inhibitors.
Clinical terms
- PDE5: enzyme broken down to regulate blood flow in penile tissue.
- cGMP: intracellular messenger that causes smooth muscle relaxation.
- CYP3A4: main enzyme metabolising tadalafil; inhibitors increase drug levels.
- Onset / half‑life: onset 30–60 minutes; half‑life consistent with prolonged duration.
Metabolism: tadalafil is predominantly metabolised by CYP3A4, which has implications for interactions with protease inhibitors and some azole antifungals.
Indications and off‑label uses
MHRA‑approved uses
Tadalafil is authorised for erectile dysfunction and some licensed tadalafil products are authorised for benign prostatic hyperplasia depending on the product licence.
The Tadarise brand itself is not MHRA-licensed; licensed tadalafil generics are available in the UK.
Off‑label practices in NHS and private care
Combination tablets such as tadalafil plus dapoxetine (Super Tadarise) are used in practice for patients with both ED and premature ejaculation but require careful assessment because of added adverse effect burden.
Off‑label prescribing should include documented discussion of risks and benefits, informed consent, monitoring plans and clear documentation in clinical records.
- MHRA‑licensed indications: erectile dysfunction; some tadalafil preparations for benign prostatic hyperplasia.
- Common off‑label scenarios: combination therapy for ED and premature ejaculation using combination generics not always authorised in the UK.
Alternatives matrix
NHS prescribing alternatives (comparison table)
| Drug | Typical dose | Onset | Duration | Common AEs | Notes |
|---|---|---|---|---|---|
| Tadalafil (generics) | 10–20 mg | 30–60 mins | Up to 36 hours | Headache, back pain, flushing | Long window for spontaneity. |
| Sildenafil (Viagra, generics) | 50 mg typical | 30–60 mins | 4–6 hours | Headache, flushing, dyspepsia | Shorter duration, quicker offset. |
| Vardenafil (Levitra) | 10 mg typical | 30–60 mins | 6–8 hours | Headache, flushing | Alternative PDE5 inhibitor. |
Pros and cons checklist
- Tadalafil: pro — long duration; con — longer exposure to side effects and interactions.
- Sildenafil: pro — shorter duration, may suit planned activity; con — less spontaneity.
- Vardenafil: pro — alternative for those intolerant to others; con — similar interaction profile.
Clinical decision checklist: discuss spontaneity preference, comorbidities, current medications and contraindications before selecting an agent.
Common questions
- Can I take Tadarise with other medicines? — Only after checking: always check for nitrates and CYP3A4 interactions and disclose all medicines to your GP or pharmacist.
- How long before sex should I take it? — Typically 30–60 minutes before activity; effects can last up to 36 hours.
- What if I get a prolonged erection? — Priapism lasting over 4 hours is a medical emergency; go to A&E immediately.
When to seek urgent help: priapism, chest pain, severe dizziness or fainting, sudden vision or hearing loss.
Registration and regulation
MHRA approval process
The MHRA regulates medicine licensing and safety reporting in the UK and approves active substances and licensed products for UK use.
Tadalafil is licensed in the UK in other products, but the Tadarise brand is not MHRA-licensed.
NHS prescribing framework
Prescribers should favour MHRA‑authorised generics or follow lawful importation procedures for unlicensed medicines and must document the rationale for product choice in the medical record.
Encourage reporting of suspected adverse reactions via the MHRA Yellow Card scheme and keep electronic prescribing records to document counselling and monitoring.
- Process flow: prescribe → dispense → monitor/report.
Storage and handling
UK household storage (cold/damp climate)
Store tadalafil tablets below 30°C in the original packaging, protected from moisture and light.
Avoid storing medicines in bathrooms or other damp locations in UK homes; a bedroom cupboard away from heat and steam is preferable.
Keep all medicines out of reach of children and pets.
Guidance from NHS and pharmacists
When travelling, keep tablets in carry‑on luggage at moderate temperatures and retain packaging and leaflets for pharmacy or customs queries.
Dispose of expired or unused tablets via pharmacy take‑back schemes rather than household waste.
- Storage steps: keep in original blister, avoid damp areas, do not exceed 30°C.
- Travel advice: carry in original box, keep with hand luggage, keep within recommended temperature range.
- Disposal: return to pharmacy for safe disposal.
Guidelines for proper use
UK pharmacist counselling style
Confirm the indication and obtain a cardiovascular history before recommending tadalafil.
Verify absence of nitrates, review all medications for CYP3A4 interactions and discuss dosing and timing (30–60 minutes before sexual activity).
Explain common adverse effects such as headache, flushing and back pain and provide clear advice on urgent signs like priapism or chest pain.
NHS patient safety advice
Advise patients to avoid driving or heavy machinery if they experience dizziness or visual disturbance after taking tadalafil and record this counselling in the patient record.
For combination products containing dapoxetine, review contraindications such as current SSRI/MAOI therapy and discuss serotonin‑related effects and cardiac risk.
- Pharmacist counselling checklist: cardiac history, concomitant medicines, correct dose/timing, side effects, when to seek urgent care.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | Greater London | 9–21 days |
| Birmingham | West Midlands | 9–21 days |
| Manchester | Greater Manchester | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | West Yorkshire | 9–21 days |
| Sheffield | South Yorkshire | 9–21 days |
| Bristol | South West | 9–21 days |
| Liverpool | Merseyside | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Newcastle | Tyne and Wear | 9–21 days |
| Nottingham | Nottinghamshire | 9–21 days |
| Southampton | Hampshire | 9–21 days |
| Plymouth | Devon | 9–21 days |